What is ASKP?
The American Society of Ketamine Physicians is a group of professionals dedicated to the safe clinical use of ketamine for mental health disorders and pain conditions.
The mission of the American Society of Ketamine Physicians
- to advocate for the safe and effective use of ketamine in the treatment of mental illness and pain disorder
- to promote high scientific, ethical, and professional standards among physicians providing ketamine therapy for mental illness and pain disorders
- to maximize quality of care by furthering knowledge, collaboration, and the exchange of ideas and research in the use of ketamine and other psychotropic medications for the treatment of mental illness and pain disorders.
- to expand access to ketamine therapy nationwide
Basics of Administration
All of the providers in our group ascribe to the same basic tenets of safety when administering Ketamine for Non-Anesthetic Indications (KNAI).
1. Patients should be screened for and have been found to have a condition that is appropriate for ketamine treatment – Unipolar Major Depression, Bipolar Depression, PTSD, OCD, Fibromyalgia, CRPS and chronic pain.
2. A full history and physical including psychiatric disorders and substance abuse disorders should be completed in the patient’s chart.
3. The patient’s medications and allergies should be documented to reduce reasonable risk of medication interaction and side effects.
4. Given the off-label nature of ketamine use for these disorders, appropriate consent should be obtained.
5. The usual starting dose for patients should be .5 mg/kg to 1 mg/kg IV over 40-60 minutes. Dose escalation may be necessary to achieve desired response. Chronic pain conditions typically require higher doses over longer periods. A practitioner should have their established protocol either published online, or be willing to share with other practitioners.
6. The patient’s vital signs should be monitored during administration and return to pre-administration values before discharge from the clinic. A provider credentialed in ACLS should be present during the administration as well.
7. Patients receiving ketamine therapeutically should not be allowed to drive themselves home from their appointment, or for 12 hours after their infusion.
8. We do not support the use of medically unsupervised parenterally administered ketamine.